Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17381374 | 0.94 | TDP1 (0.43) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21541111 | 0.90 | MEN1 (0.49) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21541319 | 0.88 | CA1 (0.44) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL15498944 | 0.86 | CAPN1 (0.44) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL25913008 | 0.85 | TDP1 (0.46) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL31467206 | 0.85 | TDP1 (0.51) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL20346566 | 0.85 | TDP1 (0.40) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21602829 | 0.85 | KMT2A (0.46) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL20346568 | 0.84 | TDP1 (0.48) | TDP1ATMMAPTNPSR1MEN1 | |
| SCHEMBL21902490 | 0.84 | MEN1 (0.47) | TDP1ATMMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | INTOCELL INC. (KR) | 2021-07-20 | — | — | US | disclosed |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | INTOCELL INC. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065343-B2 | Compound bearing beta-galactoside-introduced self-immolative linker | DDOST, B3GAT3, GALNT10 | TDP1 1893/4885ATM 4794/4885MAPT 1158/4885 |
| US-20190328902-A1 | Compound Bearing Beta-Galactoside-Introduced Self-Immolative Linker | DDOST, B3GAT3, GALNT10 | TDP1 1893/4885ATM 4794/4885MAPT 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.